Publications by authors named "A Protheroe"
Article Synopsis
- Testicular germ cell tumours (TGCT) are the most common cancers found in young men, including seminoma and non-seminoma types.
- This study uses whole genome sequencing to analyze adult TGCTs, providing a detailed genomic profile that includes mutations, structural variations, and DNA amplifications.
- The research uncovers correlations between genetic changes and the different growth patterns of TGCT subtypes, highlighting late genomic duplication in some cases and a common immune disruption mechanism in seminomas.
Article Synopsis
- Taxane-based chemotherapy, specifically paclitaxel, is commonly used for treating platinum- and immunotherapy refractory metastatic urothelial carcinoma (mUC), but survival outcomes are generally poor and biomarkers for predicting outcomes are lacking.
- A study was conducted using whole-transcriptome profiles from patients enrolled in a trial (PLUTO) to evaluate gene signatures related to survival, focusing on factors like immuno-oncology, angiogenesis, and genome instability.
- Results indicated that patients with high expressions of genome instability and evading growth suppressors experienced significantly better progression-free survival (PFS) and overall survival (OS), while activation of angiogenesis was associated with worse outcomes across both treatment cohorts.
Here, in a multi-ancestry genome-wide association study meta-analysis of kidney cancer (29,020 cases and 835,670 controls), we identified 63 susceptibility regions (50 novel) containing 108 independent risk loci. In analyses stratified by subtype, 52 regions (78 loci) were associated with clear cell renal cell carcinoma (RCC) and 6 regions (7 loci) with papillary RCC. Notably, we report a variant common in African ancestry individuals ( rs7629500 ) in the 3' untranslated region of VHL, nearly tripling clear cell RCC risk (odds ratio 2.
View Article and Find Full Text PDFBackground And Objective: The tyrosine kinase inhibitors cabozantinib and axitinib have been widely used in England to treat advanced renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy, but data on real-world usage remain limited. Our objective was to describe the real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma who received second-line or later-line (≥ 2L) cabozantinib or axitinib after vascular endothelial growth factor-targeted therapy in clinical practice in England.
Methods: This retrospective cohort study used clinical practice data (collected 2011-20) from the English Cancer Analysis System database.
Background: In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available.
Methods: Treatment-emergent adverse events (TEAEs) for patients receiving darolutamide for a median of 38 months (n = 13) are described in this pooled analysis of individual patient data from phase 1/2 studies.
Results: All patients reported TEAEs (mostly grade 1/2).